Open AccessPneumococcal Conjugate Vaccines Overcome Splenic Dependency of Antibody Response to Pneumococcal Polysaccharides
Author(s) -
Mijke A. Breukels,
André Zandvoort,
Germie P. J. M. van den Dobbelsteen,
Adrie Van Den Muijsenberg,
Monique E. Lodewijk,
Michel Beurret,
Pieter Klok,
Wim Timens,
Ger T. Rijkers
Publication year - 2001
Publication title -
infection and immunity
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.508
H-Index - 220
eISSN - 1070-6313
pISSN - 0019-9567
DOI - 10.1128/iai.69.12.7583-7587.2001
Subject(s) - streptococcus pneumoniae , pneumococcal polysaccharide vaccine , immunology , pneumococcal infections , vaccination , antibody , conjugate vaccine , conjugate , splenectomy , microbiology and biotechnology , polysaccharide , spleen , biology , serotype , pneumococcal vaccine , phagocytosis , immunization , virology , pneumococcal disease , antibiotics , mathematical analysis , biochemistry , mathematics
Protection against infections with Streptococcus pneumoniae depends on the presence of antibodies against capsular polysaccharides that facilitate phagocytosis. Asplenic patients are at increased risk for pneumococcal infections, since both phagocytosis and the initiation of the antibody response to polysaccharides take place in the spleen. Therefore, vaccination with pneumococcal polysaccharide vaccines is recommended prior to splenectomy, which, as in the case of trauma, is not always feasible. We show that in rats, vaccination with a pneumococcal conjugate vaccine can induce good antibody responses even after splenectomy, particularly after a second dose. The spleen remains necessary for a fast, primary response to (blood-borne) polysaccharides, even when they are presented in a conjugated form. Coadministration of a conjugate vaccine with additional nonconjugated polysaccharides of other serotypes did not improve the response to the nonconjugated polysaccharides. We conclude that pneumococcal conjugate vaccines can be of value in protecting asplenic or hyposplenic patients against pneumococcal infections.